Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.

Launched by BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY, DHAKA, BANGLADESH · Aug 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the cost-effectiveness of two types of diabetes medications, Sulfonylureas and DPP4 inhibitors, when used together with Metformin in patients with Type 2 Diabetes Mellitus (T2DM) who have been diagnosed for 2 to 5 years. The goal is to find out which combination of these medications not only helps control blood sugar levels better but also offers a more affordable option for patients. Researchers will compare the health outcomes and costs associated with these two treatment groups.

To be eligible for this study, participants need to be adults aged 18 or older who have been diagnosed with Type 2 diabetes for 2 to 5 years and are currently taking either Sulfonylureas or DPP4 inhibitors along with Metformin. Participants will need to provide written consent to join the trial. If you are interested in finding out more or think you might be eligible, it’s a great opportunity to help improve diabetes care while also potentially benefiting from the study's findings.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • New onset type2 diabetes mellitus diagnosed for 2 -5 years.
• • Taking either sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.
• • Age 18 years or above.
• • Both male and female.
• • Provided written informed consent.
• Exclusion Criteria:
• • Unwillingness to participate or unwillingness to give written informed consent.
• • Patients on Insulin therapy or monotherapy with metformin since the time of diagnosis.
• • Taking other than sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.
• • Diabetes related complications at the time of diagnosis.